Inactive Instrument

Zymergen Inc.

Equities

ZY

US98985X1000

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zymergen Inc. Went Out of Business CI
Liquidation Plan Approved for Zymergen Inc. CI
Motion for Exclusivity Period Extension Approved For Zymergen Inc. CI
First Motion for Exclusivity Period Extension Filed by Zymergen Inc. CI
Disclosure Statement Approved for Zymergen Inc. CI
Amended Liquidation Plan and Disclosure Statement Filed by Zymergen Inc. CI
Liquidation Plan and Disclosure Statement Filed by Zymergen Inc. CI
Motion for Joint Administration Approved for Zymergen Inc. CI
Motion for Asset Sale Filed by Zymergen Inc. CI
Motion for Joint Administration Filed by Zymergen Inc. CI
Zymergen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Zymergen Inc.(NasdaqGS:ZY) dropped from S&P TMI Index CI
Ginkgo Bioworks Holdings Closes Zymergen Acquisition MT
Zymergen Inc. Announces Executive Changes CI
Zymergen Inc.(NasdaqGS:ZY) dropped from NASDAQ Composite Index CI
Ginkgo Bioworks Holdings, Inc. completed the acquisition of Zymergen Inc. (NasdaqGS:ZY) from a group of shareholders. CI
Zymergen Says It Cut 80 More Jobs; Co-Founder Zach Serber Stepping Down as Chief Science Officer MT
Zymergen Inc. Announces Stepping Down of Zach Serber as Co-Founder and Chief Science Officer and A Member of It’S Board of Directors, Effective as of September 22, 2022 CI
Zymergen Inc. Announces Further Reduction in Force CI
Top Premarket Gainers MT
Zymergen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
North American Morning Briefing : Growth Stocks -2- DJ
UBS Adjusts Zymergen Price Target to $2.60 From $4, Maintains Neutral Rating MT
JPMorgan Upgrades Zymergen to Neutral From Underweight MT
Transcript : Ginkgo Bioworks Holdings, Inc., Zymergen Inc. - M&A Call
Chart Zymergen Inc.
More charts
Zymergen Inc. integrates computational and manufacturing technologies to design, develop, and commercialize bio-based products in a range of industries. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.
More about the company
  1. Stock
  2. Equities
  3. Stock Zymergen Inc. - Nasdaq
  4. News Zymergen Inc.
  5. Zymergen : Forecasts No Revenue This Year Due to Commercial Pipeline Problems; Shares Plunge in Pre-Market